AURX (Nuo Therapeutics) Tariff Resilience Score: 6/10 (As of Jul. 09, 2026)


AURX Nuo Therapeutics Inc AURX
33 GF Score
Price $0.96
GF Value $4.28
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Nuo Therapeutics Tariff Resilience Score?

Nuo Therapeutics AURX 33 Tariff Resilience Score is 6 as of Jul. 09, 2026. GuruFocus rates AURX with a GF Score™ of 33/100 and a GF Value™ of $4.28 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,368 Biotechnology companies, Nuo Therapeutics ranks better than 75.95% on this metric.

Nuo Therapeutics has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

Nuo Therapeutics has Nuo Therapeutics, operating in the medical sector, faces moderate tariff risks. While medical products often have exemptions, any reliance on imported raw materials could pose cost challenges if tariffs increase.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Nuo Therapeutics might have Average Resilient.

Nuo Therapeutics  (OTCPK:AURX) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Nuo Therapeutics Tariff Resilience Score Related Terms

AURX vs PDSB, LTRN, VERU: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Nuo Therapeutics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nuo Therapeutics Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nuo Therapeutics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Nuo Therapeutics's Tariff Resilience Score falls into.


AURX
33GF Score
Nuo Therapeutics Inc AURX
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 6 mean?
Nuo Therapeutics (AURX) has a Tariff Resilience Score of 6 as of Jul. 09, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Nuo Therapeutics ranks #329 out of 1368 companies in the Biotechnology industry, placing it in the top 24%.
Is Nuo Therapeutics' Tariff Resilience Score too high?
Nuo Therapeutics' current Tariff Resilience Score is 6. The Biotechnology industry median Tariff Resilience Score is 4.00. Nuo Therapeutics' value of 6 is 50% above this industry median. Based on the distribution chart, Nuo Therapeutics ranks #329 out of 1368 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Nuo Therapeutics has a GF Score™ of 33/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nuo Therapeutics' Tariff Resilience Score compare to PDSB and LTRN?
According to the Biotechnology industry distribution chart, Nuo Therapeutics ranks #329 out of 1368 companies for Tariff Resilience Score. This places Nuo Therapeutics in the top 24% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Nuo Therapeutics' value of 6 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,368 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nuo Therapeutics's current Tariff Resilience Score of 6 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nuo Therapeutics's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nuo Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Nuo Therapeutics (AURX) is currently considered Possible Value Trap. The stock's GF Value™ is $4.28, compared to a current price of $0.96 — trading 77.6% below its estimated fair value. The current Tariff Resilience Score is 6 and 50% above the Biotechnology industry median of 4.00. Nuo Therapeutics' overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Nuo Therapeutics (AURX), the current Tariff Resilience Score is 6 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nuo Therapeutics (AURX) Overvalued in 2026?

Based on GuruFocus' analysis, Nuo Therapeutics stock appears to be undervalued. The current stock price of $0.96 is trading 77.6% below its estimated GF Value™ of $4.28. GuruFocus considers Nuo Therapeutics to be Possible Value Trap.

Key valuation signals for AURX:

  • Tariff Resilience Score: 6
  • GF Value™: $4.28 vs. price of $0.96 (77.6% below fair value)
  • GF Score™: 33/100 with 4 warning signs
  • Industry Position: 50% above the Biotechnology median (#329 of 1368)

No single metric tells the full story. See the AURX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nuo Therapeutics Business Description

Address 8285 El Rio Street, Suite 190, Houston, TX, USA, 77054
Nuo Therapeutics Inc is a commercial-stage medical device company engaged in developing and marketing products for chronic wound care. The company operates as a single segment focused on regenerative therapies that utilize autologous (patient-derived) biological materials to promote natural healing. Its primary commercial product is the Aurix System, a point-of-care technology that produces platelet-rich plasma (PRP) therapy from a patient's own blood for use in the treatment of chronic wounds.
33GF Score

Get the complete analysis for AURX

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.96
Price
$4.28
GF Value